Hospital
Mercy Medical Center-Dubuque
Mercy Medical Center-Dubuque was paid $5.23M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 99283, emergency room visit (moderate) — 36% of everything it billed.
33Billing provider infoMERCY MEDICAL CENTER-DUBUQUE
DUBUQUE, IA 52001
DUBUQUE, IA 52001
33aNPI1659348506assigned 02/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.23M
24GClaims124,924
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#17 of 29
Median peer was paid$6.37M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,337 | $793K | |
| 2019 | 21,206 | $822K | |
| 2020 | 16,995 | $554K | |
| 2021 | 22,072 | $897K | |
| 2022 | 20,958 | $992K | |
| 2023 | 16,742 | $768K | |
| 2024incomplete | 9,614 | $401K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 14,965 | 13,887 | $1.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 9,595 | 8,846 | $1.81M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 4,070 | 3,866 | $296K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 2,490 | 2,262 | $249K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 697 | 618 | $181K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.1% | 1,265 | 316 | $60K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,237 | 1,128 | $58K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 1.1% | 539 | 509 | $57K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 17,783 | 15,873 | $56K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 2,248 | 1,456 | $55K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,528 | 1,162 | $51K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,149 | 987 | $50K |
76 more codes
| 86900 | <1% | 682 | $48K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,584 | $43K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 454 | $42K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,585 | $42K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 139 | $35K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,113 | $31K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 769 | $20K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 161 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 361 | $12K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 150 | $12K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 609 | $10K |
| 90837 | Psychotherapy session, about an hour | <1% | 173 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 158 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 164 | $7K |
| 86803 | <1% | 702 | $7K | |
| 86780 | <1% | 645 | $7K | |
| 86762 | <1% | 619 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 50 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 973 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,355 | $5K |
| 87340 | <1% | 615 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 223 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,506 | $4K |
| 87210 | <1% | 1,369 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 162 | $3K |
| 82950 | <1% | 357 | $3K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 43 | $2K |
| 90686 | <1% | 169 | $2K | |
| 86850 | <1% | 795 | $2K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 30 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 50 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 65 | $1K |
| 88142 | <1% | 74 | $1K | |
| 87081 | <1% | 250 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 13,563 | $1K |
| 59430 | <1% | 14 | $819.24 | |
| 81025 | <1% | 227 | $737.65 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 128 | $719.24 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 102 | $546.77 |
| 81000 | <1% | 7,256 | $457.57 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 121 | $344.72 |
| 88141 | <1% | 26 | $305.62 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 125 | $161.70 |
| 85018 | <1% | 69 | $139.57 | |
| 85014 | <1% | 69 | $139.35 | |
| 86787 | <1% | 16 | $135.99 | |
| 83605 | <1% | 2,761 | $118.66 | |
| 84484 | <1% | 722 | $64.45 | |
| 86140 | <1% | 2,604 | $47.73 | |
| 86901 | <1% | 684 | $24.05 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 84 | $15.70 |
| 83690 | <1% | 461 | $12.91 | |
| 87581 | 0% | 28 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 164 | $0.00 |
| 83880 | 0% | 43 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 63 | $0.00 |
| 85652 | 0% | 26 | $0.00 | |
| 81001 | 0% | 123 | $0.00 | |
| 83735 | 0% | 46 | $0.00 | |
| 87486 | 0% | 28 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 41 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 25 | $0.00 |
| 87040 | 0% | 22 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
| 85379 | 0% | 13 | $0.00 | |
| 84145 | 0% | 233 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 186 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 907 | $0.00 |
| 85610 | 0% | 52 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 33 | $0.00 |
| 87631 | 0% | 25 | $0.00 | |
| 90715 | 0% | 32 | $0.00 | |
| 0100U | 0% | 13 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 28 | $0.00 |
| 81003 | 0% | 12 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOSTEN, MICHELLE (COO)